Royalty Pharma plc Other Current Liabilities
Royalty Pharma plc (RPRX) had Other Current Liabilities of $16.32 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Other Liabilities, Current $16.32M.
- 2026-03-31: Other Liabilities, Current $17.48M.
- 2025-12-31: Other Liabilities, Current $53.16M.
- 2025-09-30: Other Liabilities, Current $3.12M.
| Period end | Other Liabilities, Current |
|---|---|
| 2026-06-30 | $16.32M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $17.48M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $53.16M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $3.12M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $3.08M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $18.60M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $68.60M 10-K · filed 2026-02-11 |
| 2024-09-30 | $31.20M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $97.49M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $9.02M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $11.38M 10-K · filed 2025-02-12 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 |
| 2022-12-31 | $12.40M 10-K · filed 2024-02-15 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-15 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 |
| 2021-06-30 | $4.31M 10-Q · filed 2021-08-11 |
| 2020-12-31 | $18.60M 10-K · filed 2022-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |